Sanofi and VNVC sign joint declaration on vaccine production
The agreement points to new vaccine production capacity and a shift in supply toward local manufacturing.
Source →The trace
How it reaches your house.
Starting from Sanofi Pasteur, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Sanofi Pasteur →supply upSeasonal Influenza Vaccine (Cell-Based Quadrivalent)
The Sanofi-VNVC joint declaration is explicitly about expanding domestic vaccine manufacturing capacity and supply autonomy, which should increase availability of Sanofi-supplied vaccine output.
68% confidenceHop 2
Seasonal Influenza Vaccine (Cell-Based Quadrivalent) →Stands to benefitBecause Sanofi is named in the production agreement and this vaccine is tied to Sanofi Pasteur, the added local manufacturing capacity should benefit Sanofi Pasteur as a producer.
80% confidenceSeasonal Influenza Vaccine (Cell-Based Quadrivalent) →supply upThe joint declaration points to added vaccine manufacturing capacity, which should make the broader vaccines category more available.
74% confidenceHop 3
Vaccines →Shortage riskBorosilicate Glass Tubing (Type I)
Expanded local vaccine production would raise demand for sterile primary packaging and vial stock, and this is a critical 0.9-dependency input.
79% confidenceVaccines →Shortage riskSingle-Use Bioreactor Bags (Cellbag)
More cell-based vaccine capacity directly consumes more single-use bioreactor consumables, which are marked as a critical high-dependency input.
77% confidenceVaccines →Prices riseHop 4
Single-Use Bioreactor Bags (Cellbag) →Stands to benefitCytiva (formerly GE Healthcare Life Sciences)
Added vaccine capacity and local manufacturing should raise demand for Cellbag bags, benefiting Cytiva as a major supplier.
82% confidenceSingle-Use Bioreactor Bags (Cellbag) →Stands to benefitSartorius Stedim BiotechDIM.PA
More local vaccine production should increase purchases of single-use bioreactor bags, benefiting Sartorius Stedim Biotech's bioprocessing business.
81% confidenceSingle-Use Bioreactor Bags (Cellbag) →Stands to benefit
Where it lands
What you buy, and what you own.
Goods you buy
Vaccines
In the MyPRIA app, this is checked against your own holdings.